RecruitingRecruiting
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
NCT07821658 · Eisai Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A 10-Year, Postmarketing, Multicenter, Safety Surveillance Study of Lecanemab-irmb for the Treatment of Participants With Alzheimer's Disease in Real-World Clinical Practice (Using Alzheimer's Network for Treatment and Diagnostics [ALZ-NET] Registry Data)
About this study
The study will use data from the ALZ-NET registry, which is expected to include about 20,000 patients being evaluated for- or treated with- new FDA-approved AD therapies. About 6,700 (33%) of these patients are expected to be treated with LEQEMBI.
Eligibility criteria
Inclusion Criteria:
* Enrolled in ALZ-NET
* Either currently receiving or previously received lecanemab-irmb.
Exclusion Criteria:
-None
Study design
Enrollment target: 6700 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2025-05-23
Estimated completion: 2035-01-15
Last updated: 2026-09-16
Interventions
Other: No Intervention
Primary outcomes
- • Incidence and exposure-adjusted incidence rate of the adverse events of special interest (AESIs) of ARIA-E, symptomatic ARIA-E, ARIA-H, symptomatic ARIA-H, and ICH greater-than 1 cm in diameter (Baseline up to Follow-up, up to 10 years)
Sponsor
Eisai Inc. · industry
Contacts & investigators
ContactEisai Medical Information · contact · esi_medinfo@eisai.com · +1-888-274-2378
All locations (1)
Eisai Trial Site #1Recruiting
Nutley, New Jersey, United States